Medicine and Health

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

E. Garralda, M. Beaulieu, et al.

This phase 1 study explores the safety and tolerability of OMO-103, a MYC inhibitor, in patients with advanced solid tumors. The findings revealed promising insights, with several patients maintaining stable disease after treatment. This research was conducted by a team of experts including Elena Garralda and Marie-Eve Beaulieu.

00:00

Playback language: English

Related Publications

Explore these studies to deepen your understanding of the subject.

Medicine and Health

Locoregional delivery of IL-13Rx2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial

C. E. Brown, J. C. Hibbard, et al.

Medicine and Health

PSCA-CAR T cell therapy in metastatic castration-resistant prostate cancer: a phase 1 trial

T. B. Dorff, M. S. Blanchard, et al.

Medicine and Health

Target engagement and immunogenicity of an active immunotherapeutic targeting pathological α-synuclein: a phase 1 placebo-controlled trial

P. Eijsvogel, P. Misra, et al.

Medicine and Health

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial

J. Rodón, S. Damian, et al.

Listen, Learn & Level Up

Over 10,000 hours of research content in 25+ fields, available in 12+ languages.

No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.

listen to research audio papers with researchbunny